Study highlights factors that may affect fertility projections
A research team from the Department of Developmental Neuroscience at the Tohoku University Graduate School of Medicine has revealed further details about this phenomenon with their recent publication in PLOS ONE.
The research team, led by doctoral student Misako Tatehana and Professor Noriko Osumi, performed immunohistochemical analysis of the testis in three-month-old mice before performing the same analysis on mice aged 12 months or older.
Tatehana and her team analyzed histone proteins during the 12-step spermatogenesis process. Histone proteins undergo chemical modifications during spermatogenesis, thereby affecting gene expression. More specifically, the team looked at the seven methylations and one acetylation .
They cataloged these as epigenetic markers -- modifications that affect the expression of the gene without changing the DNA base sequence of the genome itself.
Comparisons of the markers between the younger and older mice using imaging quantification techniques revealed that the latter had higher amounts of the modified histone protein, H3K79me3. A previous study by Professor Osumi found a correlation between the amount of H3K79me3 in sperm and abnormal speech communication in pups, making it a predictive marker of neural-developmental disorders.
This new finding signals that paternal aging potentially affects neurodevelopment in humans. Further research on the matter hopes to develop greater diagnostic methods for disorders stemming from the risk of advanced paternal age. Source:
Tohoku University Journal reference:
Tatehana, M., et al. (2020) Comprehensive histochemical profiles of histone modification in male germline cells during meiosis and spermiogenesis: Comparison of young and aged testes in mice. PLOS ONE . doi.org/10.1371/journal.pone.0230930 .
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology